Abstract Landmark studies of the status of DNA damage checkpoints and associated repair functions in preneoplastic and neoplastic cells has focused attention on importance of these pathways in cancer development, and inhibitors of repair pathways are in clinical trials for treatment of triple negative breast cancer. Cancer heterogeneity suggests that specific cancer subtypes will have distinct mechanisms of DNA damage survival, dependent on biological context. In this study, status of DNA damage response (DDR)-associated proteins was examined in breast cancer subtypes in association with clinical features; 479 breast cancers were examined for expression of DDR proteins cH2AX, BRCA1, pChk2, and p53, DNA damagesensitive tumor suppressors Fhit and Wwox, and Wwoxinteracting proteins Ap2a, Ap2c, ErbB4, and correlations among proteins, tumor subtypes, and clinical features were assessed. In a multivariable model, triple negative cancers showed significantly reduced Fhit and Wwox, increased p53 and Ap2c protein expression, and were significantly more likely than other subtype tumors to exhibit aberrant expression of two or more DDR-associated proteins. Disease-free survival was associated with subtype, Fhit and membrane ErbB4 expression level and aberrant expression of multiple DDR-associated proteins. These results suggest that definition of specific DNA repair and checkpoint defects in subgroups of triple negative cancer might identify new treatment targets. Expression of Wwox and its interactor, ErbB4, was highly significantly reduced in metastatic tissues vs. matched primary tissues, suggesting Cigdem Himmetoglu, Rafael E. Jimenez, and Susan M. Geyer are equal contributors.
Introduction
Chromosome fragile sites are preferential targets of replication stress, resulting in deletions involving encoded fragile genes [1, 2] . The most commonly altered fragile sites are FRA3B/FHIT and FRA16D/WWOX at chromosomes 3p14.2 and 16q23.3. Fhit and Wwox protein expression is coordinately lost or reduced in *2/3 of breast cancers [3] and loss is more frequent in ER/PR negative breast tumors [4] . Coordinate loss of Fhit and Wwox also occurs in ductal carcinoma in situ tissues [5] , suggesting early loss during breast carcinogenesis.
Several lines of investigation have focused our interest on expression of DDR-associated proteins in breast cancer and how DNA damage-targeted tumor suppressor loss participates in DDR checkpoint activation and repair processes: (1) Reports of activated DDR checkpoints in preneoplastic lesions, accompanied by allelic FHIT deletions [6] [7] [8] and loss of expression of Fhit protein in early lesions [9] [10] [11] , coupled with our knowledge that Fhit expression loss contributes to aberrant DDR [12] , suggested that deletions at the FHIT gene could activate the DDR and reduction in Fhit protein expression could contribute to neoplastic progression. (2) The discovery that BRCA1/2 deficient breast cancer-derived cell lines were sensitive to killing by inhibitors of PARP enzymatic activity [13, 14] , through a synthetic lethal mechanism involving loss of homologous recombination repair (HRR) and blocking of other repair pathways by PARP inhibition [15] [16] [17] . (3) BRCA1-deficient breast cancers are mostly triple negative (TN), a subtype associated with defects in some types of DNA repair [18] and endowed with ''BRCAness'' [19] , and Fhit expression is lost in *90% of BRCA1 and 2-mutated breast cancers [20] [21] [22] . Thus, we were interested in how loss of expression of Fhit and Wwox, might contribute to ''BRCAness'' and to responses to aberrant DDR checkpoints or repair pathways.
Chk2 and Chk1, downstream targets of ATM and ATR, have roles in regulation of checkpoint responses [23, 24] and the absence of expression of wild type ATR or Chk1 leads to accumulation of deletions and rearrangements of fragile sites [25] . The occurrence of DNA double-strand breaks (DSBs) is followed by phosphorylation of histone H2AX by ATM or ATR; the phosphorylated protein, cH2AX, recruits, and localizes DNA repair proteins [26] , including BRCA1 [27] , to the DNA breaks.
In a study of 837 breast cancers on a tissue microarray (TMA), we observed that TN tumors showed significantly reduced Fhit and Wwox expression [4] . We then analyzed the expression of DDR-associated proteins cH2AX, pChk2, and p53 in these cases and found that increased nuclear expression of cH2AX, pChk2, and p53 was significantly more frequent in TN tumors [GG, CH, REJ, WPW, SC, RTP, CLS, KH, unpublished results]. We have continued similar studies on an independent breast cancer cohort, including all breast cancer subtypes [28] and matched primary and metastatic cases, with linked clinical and follow-up data, to gain a better understanding of the role of activated DDR-associated proteins in breast cancer subtypes and outcomes.
Materials and methods

Construction of the breast cancer TMAs
The studies were approved by the Ohio State University Institutional Review Board for studies of human subjects. Tissue Archive Services and Information Warehouse personnel of the Ohio State University Medical Center, acting as ''honest brokers'', anonymized all cases by removing identifiers and assigning random numbers before supplying slides, blocks, and linked clinical information to investigators.
The SFBCAS TMA
Breast cancer cases (824) from prior to 1998, were selected from *4000 women who contributed pathological and clinical outcome data to the National Comprehensive Cancer Network (NCCN) breast cancer database [29] . Selection criteria included all invasive breast cancers for which clinical information, including stage, grade, histologic type, treatment, site of first recurrence, and disease-free and overall survival were available. The parrafin-embedded tissue blocks were reviewed by pathologists (CM and REJ) and 564 were acceptable for the TMA, 303 for which there was tumor only, 226 with tumor and metastases, and 35 with only metastatic tissue. Cores (0.6 mm) from each tumor and metastasis were placed in quadruplicate blocks, with 50 assorted control tissues. The clinical information for the primary breast cancers included histological tumor type, grade and ER, PR, and ErbB2 status of tumors abstracted from clinical records and pathology reports.
Immunohistochemical analysis BRCA1, pChk2, cH2AX, p53, Fhit, Wwox, Wwox-interacting proteins (Ap2c, Ap2a, ErbB4), ErbB3, CK5/6, EGFR immunostainings were performed on TMA sections as described [3] [4] [5] . Specific antisera used, staining methods and detection kits are listed in Table 1 . Expression of Fhit, Wwox, and CK5/6 was cytoplasmic, Ap2a, Ap2c, pChk2, and cH2AX nuclear, EGFR, ErbB3, and ErbB4 cytoplasmic and membranous, and BRCA1 nuclear and cytoplasmic. Cytoplasmic expression in C10% of tumor cells for CK5/6, membranous staining in C10% of tumor cells for EGFR and nuclear staining in C10% for Ap2a, Ap2c, was accepted as positive. Fhit and Wwox staining in tumors was scored according to intensity: absent, highly reduced, reduced staining, or strong expression [4, 5, 30] , though final scores were collapsed to two categories (lost/very reduced vs. strong/moderate expression for some statistical modeling); [50% of cells for nuclear cH2AX and [25% of cells for nuclear pChk2, C50% strong expression of p53, any membrane staining of ErbB3 and ErbB4 was accepted as positive. BRCA1 nuclear expression was scored as \ or [90% and reduced cytoplasmic BRCA1, ErbB3, and ErbB4 expression was noted when present. Four pathologists (GG, REJ, WPW, SC) scored the slides and were blinded to the breast cancer subtype; two pathologists (GG, CH) converted scores to numbers, selected cut off values for each marker and entered data into excel and SPSS files. The 423 breast cancers that could be scored were divided into subtypes of breast cancer as defined by their IHC profiles using designated stains [31, 32] Relationships of marker expression and clinical features were evaluated in relation to disease subtype using univariate and multivariable logistic regression models. Variable selection in the multivariable models was explored by the leaps and bounds approach [33] . We also assessed potential multivariable models based on the univariate logistic regression models.
Disease-free survival (DFS) was assessed from the time patients were disease-free to date of recurrence and/or death. Patients with metastases at diagnosis were excluded from DFS analyses and only subjects with stage I-III tumors at diagnosis were included. Kaplan-Meier and Cox regression models were used to evaluate DFS, where differences in DFS distributions were evaluated based on clinical characteristics and marker expression. The P values reported in relation to DFS correspond to log rank tests unless otherwise noted. Since we simultaneously evaluated multiple markers along with clinical characteristics of interest, we corrected for multiple comparisons using the Benjamini-Hochberg method to control for false discovery rates. Statistical significance was defined by ranking observed P values from smallest to largest and comparing each ith P value to (i/m)*Q, where m = number of P values for that set of analyses and Q is the chosen constraint for false discovery rate (FDR, here set to 0.05). All analyses were conducted using PASW Statistics (SPSS) v. 18 and R version 2.9.0. Table 2 ).
Results
Breast cancer characteristics
As noted in earlier studies, there were significant differences in the ages at diagnosis by breast cancer subtype; the median age for TN cases was 47 years, while for luminal A, B, and ErbB2??? median ages were 55, 51, and 52 years, respectively (P = 0.003).
DDR-associated protein expression in breast cancer
The SFBCAS TMA There were data on 423 breast cancer subjects, including biochemical markers determined by IHC and integrated clinical data (Table 2 for summary). We assessed associations among pairs of proteins in this TMA (Supplementary  Table S1 ): pChk2 and cH2AX expression were highly positively correlated only with each other (P \ 0.00001); BRCA1 nuclear expression was significantly positively correlated with expression of cytosolic ErbB3 (P = 0.00004) and with Fhit and Wwox expression (each P = 0.02), indications of an intact HRR pathway in cancers expressing nuclear BRCA1. Expression of the transcription factor Ap2c was highly, positively associated with expression of pChk2 and p53 (P \ 0.001).
The DDR checkpoint proteins, cH2AX, pChk2, and p53, were expressed more frequently in TN and basal-like cancers vs. other subtypes ( Fig. 1 for illustration of results, Fig. 2 for representative photos of IHC results). As observed by others [19] , we find that TN tumors frequently show reduced expression of BRCA1. The bar graph in Fig. 1 shows that highly positive BRCA1 expression (90% of cells with nuclear expression) was rare in the TN tumors (Table S2 lists expression scoring results for specific markers relative to clinical features). By univariate modeling, BRCA1 nuclear expression was significantly, inversely associated with ER/PR negativity (P = 0.0004) and specifically with TN breast cancer subtype (P = 0.009, Table 3 ). p53 expression was also highly correlated with TN and basal-like subtypes (P \ 0.00001).
In order to investigate more broadly the association of alterations to expression of DDR proteins in TN breast cancers, a DDR score was devised, based on frequency of altered or activated expression of nuclear BRCA1, cH2AX, pChk2, Fhit, p53; i.e., proteins involved in recognition of DNA breaks (cH2AX), in checkpoint activation in response to breaks (pChk2, p53), or DNA repair (Fhit, BRCA1). The number of deleteriously expressed markers was summed, where reduced nuclear BRCA1 or Fhit, or elevated cH2AX, p53, or pChk2 were considered deleterious. The median number of markers with deleterious expression was 2. TN cancers had a median of 3 aberrantly expressed markers vs. non-TN cancers (median = 3 vs. 2, P \ 0.0001). Across the 279 tumors with data for all 5 markers, only 4 had deleterious expression of all 5 markers (2 luminal, 2 TN); 17 had no deleterious expression of any markers (all luminal) (data for stage I-III cases with recurrences summarized in Table S3 ). Based on logistic regression models, DDR score (0 vs. 1 vs. 2 vs. 3 vs. 4 vs. 5) was significantly associated in the univariate setting with TN status (P \ 0.00001). Analyses of the DDR protein scores supported a collapsing of the scores into two groups: 0-1 vs. 2-5; this collapsed grouping of 0-1 vs. 2-5 was also significantly associated with TN status (OR = 6.2, P = 0.003, Table 3 ). By this assay, TN cancers were 69 more likely to exhibit aberrant expression of 2 or more DDR-associated proteins. The distribution of scores between TN and non-TN subjects is shown in the box plot in Fig. 3 . Fig. 1 Graphical representation of expression of DDR proteins in TN cancers. In studies of the breast cancers on the SFBCAS TMA, DDR proteins were expressed more frequently in TN and basal-like tumors. The numbers to the lower left of each graph represent the cut-off percentages for scoring a tumor positive or negative; i.e., for pChk2, tumors were scored positive if [25% of nuclei were positive for expression and were scored negative if \25% of nuclei were expressing pChk2. For cH2AX the cut-off was at 50% and for BRCA1 at 90%. Because percentages were calculated using denominators that included cases for which scores were not available, the percentages will not necessarily sum to 100% across the expression groups for individual markers
Tumor suppressors and interacting proteins in association with breast cancer subtypes
As shown in Table 3 , expression of various proteins was significantly associated with subtype groups in the univariate setting: lost or reduced Fhit and Wwox expression was strongly associated with TN tumors (P = 0.0003 and 0.0002), as were absence of ErbB3 cytosolic expression and positive membrane expression of ErbB4 (Table 3) . Other significant factors for TN status in the univariate setting were: Ap2c (P = 0.00005), reduced BRCA1 nuclear expression (P = 0.009) and p53 (P \ 0.00001) expression.
When protein expression markers were evaluated in the multivariable setting in relation to TN status (Table 4) , four markers remained significant: reduced Wwox and Fhit (P = 0.002 and 0.03), and p53 and Ap2c positivity (both P = 0.004). Overall, Wwox, Ap2c, and p53 remained significant across multivariable models for each of the subtype groupings (ER/PR negative, TN, and basal-like).
Primary tumors and metastases
In analyses for level of agreement between markers in tumor vs. metastatic tissue, expression of several proteins were significantly discordant, as shown in Table 5 ( for representative photographs of protein expression in matched primary and metastatic sections). Expression of Wwox was highly significantly reduced in the metastatic tissues (P \ 0.0001) vs. the primary tumor tissue; loss of cytosolic and membrane ErbB4 expression was also associated with occurence of metastases (P = 0.002 and 0.004), as was BRCA1 nuclear expression (P = 0.003).
Associations of markers and outcomes
For a subset of 330 patients, there was recurrence data available; 60 distant and 19 locoregional. Patients who developed in situ recurrences or had metastases at diagnosis were excluded from the disease-free status analyses. The resulting cohort used in the analyses was 305 nonmetastatic breast cancer subjects with data available on disease-free and recurrence status; 79 subjects had a recurrence and the median follow-up was 98 months (range: 4-242 months); only 8 subjects had \12 months follow-up. Disease-free survival of TN cancers was significantly worse than for luminal subtypes (see Fig. 5 ), as expected from earlier studies (note that ErbB2??? cases are from before introduction of trastuzamab treatment). DFS for TN cases vs. all other subtypes was also significantly worse (P = 0.0001) ( Table 6 ). DFS of cases with reduced Fhit was significantly worse and this figure remained significant when Fhit negative and mild expressers were combined together vs. moderate plus high expressers (P = 0.007, Fig. 6 ). DFS of cases with membrane ErbB4 expression Fig. 3 Boxplot of DDR scores, for number of aberrantly expressed DDR-associated proteins in TN vs. non-TN breast cancers. The DDRassociated proteins assessed were: altered or activated expression of nuclear BRCA1, cH2AX, pChk2, Fhit, p53; i.e., proteins involved in recognition of DNA breaks (cH2AX), in checkpoint activation in response to breaks (pChk2, p53), or in DNA repair (Fhit, BRCA1) a OR est from these models reflect the exponential of the multivariable logistic regression model parameter estimates. In looking at the models of TN vs. other, and basal-like vs. other, these same variables that are statistically significant in the multivariable models shown above were also significant factors in multivariable models using an all subsets approach to variable selection (leaps and bounds method [33] ). The only difference was that in the all subsets methods, the ErbB3 cytoplasmic score was also a significant identified marker for basal-like vs. other. Also, in the all subsets method, the addition of the Fhit score did not contribute much to the overall model in determining TN vs. other was also significantly worse than others (P = 0.0013, not shown).
In univariate analyses, the following factors/markers had a P value \0.20 and were considered in the multivariable model: stage, grade, breast cancer subtype, ErbB3 (cytoplasmic), ErbB4 (membrane), Fhit and p53; grade was highly correlated with stage (P \ 0.00001) and with breast cancer subtype (P \ 0.00001). To avoid multicolinearity issues, grade was excluded from the final multivariable model. Ultimately, the three significant factors in the model for DFS were stage (P = 0.00014), breast cancer subtype (P \ 0.0001), and ErbB4 membrane score (P = 0.0065). As described above, we created a DDR marker-based score that reflected the number of DNA damage response proteins with aberrant expression in each cancer. DFS of patients differed significantly depending upon the number of deleterious markers exhibited as shown in Table S3 and Fig. 7 . Our analyses are limited by the large percentage of censored observations and the constraint that subjects needed to have data available on all five markers used to generate the DDR score.
Discussion
Associations among marker proteins BRCA1 nuclear expression was strongly, positively associated with ErbB3 cytoplasmic expression, as well as with Fhit and Wwox expression; Fhit loss was correlated with expression of p53, and strongly, positively correlated with expression of cytoplasmic ErbB3 and ErbB4; p53 was most strongly correlated with expression of Ap2c; and Wwox loss was most strongly correlated with loss of expression of ErbB3 cytoplasmic protein and with Fhit loss. The unexpected strong correlation of Fhit expression with cytoplasmic ErbB4 and Ap2a, both Wwox interactors, and correlation of Wwox and Fhit with cytosolic ErbB3, warrant mechanistic studies in breast cancer-derived cell lines.
DDR-associated proteins and breast cancer subtypes
Our studies show a previously unreported feature of TN breast cancers. Three proteins of the activated DDR checkpoint, cH2AX, pChk2, and p53, are more frequently expressed in this group of neoplasms with 67% of pChk2 positive cases being cH2AX positive; and expression of BRCA1 and Fhit, associated with aberrant DNA damage repair, are highly significantly reduced in TN cancers. Interestingly, Fhit and BRCA1 are reduced in expression together in 70.9% of cases. We do not know if cH2AX and pChk2 expression together indicate an intact-activated checkpoint or if the 70% of cH2AX positive cases that are negative for pChk2 expression are evidence of a crippled checkpoint. It would be useful to examine subtype specific breast cancer cell lines with persistently activated checkpoints for sensitivity to inhibitors of Chk2 and Chk1. In addition, since absence of BRCA1 and Fhit are not correlated with activation of the checkpoint proteins, it may be that the BRCA1 and/or Fhit-deficient TN cancers are more likely to be sensitive to PARP inhibitors, as expected from previous studies [13, 14, 17] .
So why are TN breast cancers, including the basal-like subgroup, more likely to show evidence of activated checkpoints, deleted fragile tumor suppressors, and DDR defects? It could be related to the cell type of origin for Fig. 7 DFS of patients based on breast cancer expression levels of DDR proteins. The DDR-associated proteins assessed and used in this DFS analysis were altered or activated expression of nuclear BRCA1, cH2AX, pChk2, Fhit, p53; i.e., proteins involved in recognition of DNA breaks (cH2AX), in checkpoint activation in response to breaks (pChk2, p53), or DNA repair (Fhit, BRCA1). It is likely that subtype is the driver of these differences because the DDR proteins tend to be most frequently altered in TN cancers, though the analyses are limited by the relatively large percentage of censored observations and the small numbers of cases in some subgroups, as illustrated in Table S3 these cancers. Basal-like breast tumors are enriched in breast cancer stem cells [34] [35] [36] [37] , and p53 and BRCA1 proteins may have roles in stem cells [36, 37] . Presumably stem cells, including cancer stem cells, have a longer history of cell divisions than differentiated cells, providing many more opportunities for exposure to replication stress followed by repair defects and genome instability. TN cancers do show evidence of more genomic alterations than other breast cancer subtypes [38] . It has even been suggested that reduced expression of BRCA1 and Fhit may be hallmarks of stem cells [37, 39] . The persistent expression of DDR-associated proteins observed in this study in TN cancers probably has an important role in development of these cancers.
In a relevant example, Asakawa et al. [40] studied human breast cancer biopsies and showed that treatment with DNA damaging drugs induced nuclear foci of cH2AX, conjugated ubiquitin, and Rad51 in a substantial fraction of cases. The presence of BRCA1, cH2AX, or Rad51 foci before treatment was inversely correlated with tumor response to chemotherapy. DDR competence was further evaluated by considering all four repair indicators together. A high DDR score significantly correlated with low tumor response. The results ''suggested importance of evaluation of DDR competence to predict breast cancer chemosensitivity…'' [40] .
Tumor suppressors and interactors in breast cancer subtypes
The most striking finding concerning Wwox expression was that nearly 100% of metastatic tissues showed lower Wwox expression than the matched primary tumors. This is of particular interest because recent studies have shown that siRNA-mediated knockdown of endogenous Wwox in ovarian cancer cells increased adhesion to fibronectin and WWOX-transfected cells in suspension culture displayed a proapoptotic phenotype. The authors proposed that Wwox acts as an ovarian tumor suppressor by modulating the interaction between tumor cells and the extracellular matrix and by inducing apoptosis in detached cells, suggesting a role for Wwox loss in peritoneal dissemination of ovarian cancer cells [41, 42] . Reduction of Wwox expression in metastatic tissues suggest a similar role for Wwox loss in lymph node metastasis. Expression of the Wwox-interacting protein, ErbB4, in membrane and cytosolic forms, was also significantly reduced in the metastatic lesions. Sundvall et al. [43] have reviewed aspects of ErbB4 expression and prognostic significance in breast cancer and have shown that absence of Wwox protein was associated with the number of cancer-positive axillary lymph nodes.
Ap2a and c transcription factors have been implicated in control of proliferation, differentiation, and apoptosis of normal breast epithelium and in breast cancer. It is possible that the association of Ap2c with TN cancers is related to the role of Ap2c in proliferation of the mammary gland precursor cells. A recent study [44] showed that the WWOX gene is a transcriptional target of the Ap2c transcription factor, suggesting an autoregulatory loop involving Wwox and Ap2c proteins; thus, perhaps Wwox loss in TN cancers permits nuclear Ap2c localization and upmodulation of proliferative activity.
Clinical associations
In this study, DFS of cases with ErbB4 membrane positivity and reduced Fhit was significantly worse than others, though expression of membrane ErbB4 has been associated with favorable overall survival in previous studies [45, 46] . Our current results showed that expression of both cytoplasmic and membrane ErbB4 was more frequent in TN/ basal-like tumors, and the membrane form was associated with worse DFS. Altogether, the results imply that assigning a singular ''good or bad'' role for ErbB4 in breast carcinogenesis is not straightforward [43] .
Aqeilan et al. [46] assessed the clinical significance of the Wwox-ErbB4 association in [500 breast cancers. Loss of Wwox expression was associated with unfavorable outcome, co-expression of membrane ErbB4 and Wwox was associated with favorable outcome, compared with cases with membrane ErbB4 and no Wwox immunoreactivity. In our study, Wwox was lost in nearly 100% of the metastases, and reduced cytoplasmic ErbB4 was significantly associated with metastatic tissues. Other investigators have reported that the ErbB4 cytosolic form is associated with apoptosis and favorable outcomes [45, 47] , results that seem consistent with our observation of loss of cytosolic ErbB4 in metastatic tissues. Thus, there was a strong association of loss of the Wwox signal pathway with breast cancer lymph node metastasis, a finding that is likely tied to the role of expression loss in allowing survival of tumor cells that have detached from basement membranes [41] .
